We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A3P Biomedical AB announced that the publication of the STHLM3 MRI trial including 12,750 men has been fast tracked and is now published in the renowned peer-reviewed scientific publication The Lancet Oncology1.